Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Circulation Baddour et al.
111: e394
Correction
In the AHA Scientific Statement, “Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association,” by Baddour et al (Circulation. 2005;111:e394–e434), the following correction is needed:
In Table 14 on page e417 under the heading for “Suspected Bartonella, culture negative,” the entry for doxycycline currently reads: “200 mg/kg per 24 h IV/PO in 2 equally divided doses.” It should read “200 mg/24 h IV or PO in 2 equally divided doses.”
This correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/cgi/content/full/111/23/e394.
